Clinical trial combines enzalutamide with immunotherapy for advanced prostate cancer

Immune cell

Dr. Ravi Madan, Clinical Director of the Genitourinary Malignancies Branch, is conducting a clinical trial for men who have metastatic prostate cancer but have not yet been treated with chemotherapy, abiraterone or enzalutamide. The trial will randomly assign patients to either enzalutamide with or without immunotherapy.  Enzalutamide is an FDA-approved therapy for metastatic prostate cancer.  This study, based on preliminary data, is designed to determine if immunotherapy can enhance the efficacy of enzalutamide. Contact the Medical Oncology Referral Office at 1–866–611–6310 for more information.

Summary Posted: 07/2016